Levemir (FlexTouch)
Insulin detemir – long-acting basal insulin for diabetes mellitus
Quick Facts About Levemir
Key Takeaways About Levemir
- Long-acting basal insulin: Levemir provides up to 24 hours of background insulin coverage with a relatively flat action profile and low within-subject variability
- Flexible dosing: Can be given once or twice daily; inject at the same time each day for consistent blood glucose control
- Hypoglycemia is the most common side effect: Always carry a fast-acting source of glucose and learn to recognize the symptoms of low blood sugar
- Never share pens: Even with a new needle, sharing insulin pens between patients can transmit blood-borne infections
- Suitable in pregnancy: Clinical data support the use of insulin detemir during pregnancy when clinically needed, with careful glucose monitoring
What Is Levemir (FlexTouch) and What Is It Used For?
Levemir (insulin detemir) is a long-acting basal insulin analog used to control blood sugar in people with type 1 and type 2 diabetes mellitus. It is injected subcutaneously once or twice daily and works for up to 24 hours, providing steady background insulin that helps regulate glucose levels between meals and overnight.
Levemir FlexTouch is a pre-filled disposable insulin pen manufactured by Novo Nordisk. The active substance, insulin detemir, is produced by recombinant DNA technology in Saccharomyces cerevisiae (baker's yeast). It belongs to the pharmacological class of long-acting insulin analogs, meaning its molecular structure has been modified from human insulin to achieve a prolonged duration of action.
The primary mechanism behind Levemir's extended action involves two processes: self-association of insulin detemir molecules at the subcutaneous injection site, which slows absorption, and reversible albumin binding in the bloodstream, which further prolongs its action. This dual mechanism results in a flatter, more predictable pharmacodynamic profile compared with older intermediate-acting insulins such as NPH (isophane) insulin.
Levemir is indicated for the treatment of diabetes mellitus in adults, adolescents, and children aged 2 years and older. In type 1 diabetes, it is used as part of a basal-bolus regimen alongside rapid-acting mealtime insulin (such as insulin aspart or insulin lispro). In type 2 diabetes, it can be used alone or in combination with oral antidiabetic medicines (such as metformin, sulfonylureas, or DPP-4 inhibitors) and/or GLP-1 receptor agonists, depending on the patient's needs.
Levemir is a basal insulin only – it does not cover the rapid blood sugar rises that occur after eating. People with type 1 diabetes will always need a separate rapid-acting insulin for meals. People with type 2 diabetes may or may not need mealtime insulin, depending on their level of glycemic control.
How does insulin detemir differ from human insulin?
Insulin detemir is an analog of human insulin. The amino acid threonine at position B30 has been removed, and a 14-carbon fatty acid chain (myristic acid) has been attached to the lysine amino acid at position B29. This fatty acid modification is what enables albumin binding and gives Levemir its prolonged action. The structural change does not affect insulin's ability to bind to insulin receptors on target cells but significantly changes its pharmacokinetic behavior.
Compared with NPH insulin, studies have shown that Levemir provides comparable glycemic control (as measured by HbA1c) with a significantly lower risk of nocturnal hypoglycemia and less weight gain. These advantages have been demonstrated in multiple large randomized controlled trials involving both type 1 and type 2 diabetes patients.
Pharmacokinetics at a glance
After subcutaneous injection, Levemir has an onset of action of approximately 1–2 hours, with maximum concentration occurring between 6 and 8 hours. The duration of action is up to 24 hours depending on the dose, though some patients may require twice-daily dosing for optimal 24-hour coverage. The terminal half-life is approximately 5–7 hours after subcutaneous administration. Insulin detemir is primarily degraded in the same manner as native human insulin, broken down by insulin-degrading enzymes in the liver and kidneys.
What Should You Know Before Taking Levemir?
Before starting Levemir, tell your healthcare provider about all medical conditions, current medications, allergies, and whether you are pregnant or breastfeeding. Levemir should not be used during episodes of hypoglycemia or if you are allergic to insulin detemir or any of its excipients.
Your healthcare provider will consider several factors before prescribing Levemir, including your type of diabetes, current blood glucose levels, HbA1c target, kidney and liver function, other medications, and lifestyle factors. Understanding the following contraindications, warnings, and precautions will help you use this medicine safely and effectively.
Contraindications
Levemir must not be used in the following situations:
- Hypersensitivity: Do not use if you are allergic to insulin detemir or any of the other ingredients in Levemir (disodium phosphate dihydrate, glycerol, phenol, metacresol, zinc acetate, hydrochloric acid, sodium hydroxide, and water for injections)
- Hypoglycemia: Never inject Levemir when you are experiencing an episode of low blood sugar. Treat the hypoglycemia first, then resume your normal insulin schedule
Warnings and Precautions
Several situations require special attention and close monitoring when using Levemir:
- Dose changes: Switching from another insulin product to Levemir may require a dose adjustment. Transitions should be done under medical supervision with increased blood glucose monitoring
- Illness and stress: Infections, fever, surgery, emotional stress, and other illnesses can increase insulin requirements. You may need temporary dose increases during these periods
- Renal and hepatic impairment: Kidney or liver disease may reduce insulin breakdown, potentially lowering insulin requirements. More frequent blood glucose monitoring is needed
- Thiazolidinedione combination: Using Levemir with thiazolidinediones (pioglitazone) may increase the risk of heart failure, especially in patients with pre-existing cardiac risk factors. Report any signs of swelling, weight gain, or breathlessness to your doctor
- Hypokalemia: All insulins, including Levemir, can cause a shift of potassium from the blood into cells, potentially leading to low potassium levels. This may be clinically significant in patients taking potassium-lowering medications
- Injection technique: Always rotate injection sites within the same body region (abdomen, thigh, or upper arm) to reduce the risk of lipodystrophy, which can affect insulin absorption
- Insulin pen safety: Never share your Levemir FlexTouch pen with another person, even if the needle is changed. Pen sharing carries a risk of blood-borne pathogen transmission
Hypoglycemia is the most common serious adverse effect of insulin therapy. Symptoms include sweating, trembling, rapid heartbeat, hunger, dizziness, confusion, blurred vision, and in severe cases, loss of consciousness or seizures. Always carry a fast-acting source of glucose (such as glucose tablets, juice, or sugar) and ensure that people around you know how to help in an emergency.
Pregnancy and Breastfeeding
Levemir (insulin detemir) can be used during pregnancy when clinically needed. Large observational studies and clinical trials have shown no adverse effects on pregnancy outcomes or on the health of the unborn child. Insulin requirements are highly variable during pregnancy: they typically decrease in the first trimester and increase progressively during the second and third trimesters. After delivery, insulin requirements usually return rapidly to pre-pregnancy levels.
Insulin detemir can also be used during breastfeeding. Insulin treatment of a breastfeeding mother does not pose a risk to the infant, although the mother's insulin dose may need to be adjusted. It is not known whether insulin detemir is excreted in human breast milk, but even if it were, it would be degraded in the infant's gastrointestinal tract and not absorbed into the bloodstream.
Driving and operating machinery
Hypoglycemia can impair your concentration and reaction time. If you experience symptoms of low blood sugar, do not drive or operate heavy machinery until the hypoglycemia has resolved. Patients who have reduced or absent warning symptoms of hypoglycemia (hypoglycemia unawareness) should take particular care. Your healthcare provider can advise on whether it is safe for you to drive.
How Does Levemir Interact with Other Drugs?
Many medicines can affect your blood sugar levels and may require dose adjustments when used with Levemir. Drugs that lower blood sugar (e.g., sulfonylureas, GLP-1 agonists) increase the risk of hypoglycemia, while drugs that raise blood sugar (e.g., corticosteroids, thyroid hormones) may reduce Levemir's effectiveness.
Drug interactions with insulin can be clinically significant because they may alter your blood glucose levels, potentially causing dangerous hypoglycemia or loss of glycemic control. It is essential to inform your healthcare provider about all medications you are taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements. Below is a summary of the most important interactions.
Major Interactions – Increased Risk of Hypoglycemia
The following medicines may increase the blood-sugar-lowering effect of Levemir, meaning your insulin dose may need to be reduced to avoid hypoglycemia:
| Drug / Drug Class | Examples | Mechanism | Clinical Advice |
|---|---|---|---|
| Sulfonylureas | Glimepiride, glipizide, glyburide | Stimulate pancreatic insulin secretion | Significant hypoglycemia risk; dose reduction of either agent may be needed |
| GLP-1 receptor agonists | Liraglutide, semaglutide, dulaglutide | Enhance insulin secretion and slow gastric emptying | Monitor closely; may need to reduce basal insulin dose by 10–20% |
| MAO inhibitors | Selegiline, phenelzine | May increase insulin sensitivity | Monitor blood glucose more frequently |
| ACE inhibitors | Enalapril, ramipril, lisinopril | May improve insulin sensitivity | Monitor blood glucose when starting or stopping |
| Salicylates (high dose) | Aspirin (anti-inflammatory doses) | Increase peripheral glucose utilization | Relevant only at anti-inflammatory doses (>3 g/day) |
| Beta-blockers | Propranolol, metoprolol | May mask hypoglycemia symptoms and delay recovery | Increased vigilance; may mask tremor and tachycardia |
Minor Interactions – Reduced Insulin Effect (Hyperglycemia Risk)
The following medicines may reduce the blood-sugar-lowering effect of Levemir, potentially requiring an increase in insulin dose:
| Drug / Drug Class | Examples | Mechanism | Clinical Advice |
|---|---|---|---|
| Corticosteroids | Prednisolone, dexamethasone | Increase hepatic glucose production and insulin resistance | Often need 20–40% insulin dose increase; monitor closely |
| Thyroid hormones | Levothyroxine | Increase glucose absorption and hepatic gluconeogenesis | Adjust insulin when thyroid status changes |
| Thiazide diuretics | Hydrochlorothiazide, chlorthalidone | Impair insulin secretion and increase insulin resistance | Monitor blood glucose when initiating |
| Oral contraceptives | Combined estrogen-progestogen pills | May increase insulin resistance | Monitor when starting or stopping; modest effect |
| Sympathomimetics | Salbutamol, terbutaline, epinephrine | Stimulate glycogenolysis and gluconeogenesis | Temporary increase in blood glucose; adjust if prolonged use |
| Atypical antipsychotics | Olanzapine, clozapine, quetiapine | Increase insulin resistance and impair glucose metabolism | Increased monitoring recommended; dose adjustments may be needed |
Alcohol can both increase and decrease blood sugar levels. Moderate alcohol consumption may intensify the blood-sugar-lowering effect of insulin and increase the risk of hypoglycemia, particularly overnight. If you drink alcohol, do so in moderation, always with food, and monitor your blood sugar levels closely before bedtime. Avoid heavy drinking.
What Is the Correct Dosage of Levemir?
Levemir dosing is individualized by your healthcare provider based on your blood glucose levels. It is typically given once or twice daily by subcutaneous injection. Common starting doses range from 10 units or 0.1–0.2 units/kg once daily in type 2 diabetes, and approximately one-third of total daily insulin in type 1 diabetes.
There is no universal dose of Levemir. Your healthcare provider will determine the right starting dose and adjust it over time based on your blood glucose readings, HbA1c results, and individual response. The following dosing information provides general guidance based on clinical practice and international guidelines.
Adults – Type 2 Diabetes
Starting Dose
Typically 10 units once daily (or 0.1–0.2 units/kg/day), usually given in the evening or at bedtime. The dose is then titrated (adjusted) every 3–4 days based on fasting blood glucose levels, aiming for a target of 4.0–7.0 mmol/L (72–126 mg/dL).
Maintenance Dose
Highly individual; many patients stabilize at 20–60 units per day. Some may need higher doses depending on degree of insulin resistance. Can be given once daily (usually evening) or split into two doses (morning and evening) for better 24-hour coverage.
Adults – Type 1 Diabetes
Basal-Bolus Regimen
Levemir is used as the basal component, typically providing approximately 40–50% of total daily insulin. It is administered once or twice daily in combination with rapid-acting mealtime insulin. For example, a patient requiring 40 units of total daily insulin might use 16–20 units of Levemir as basal insulin and divide the remainder among meals.
Children (aged 2 years and older)
Pediatric Dosing
Levemir is approved for children aged 2 years and older with type 1 diabetes. Dosing is individualized and calculated per kilogram of body weight. It is used as the basal component of a basal-bolus regimen. Levemir may be given once or twice daily in children; twice-daily dosing is often preferred in younger children for more stable blood glucose control.
Elderly
Dose in Older Adults
There is no specific dose adjustment for elderly patients. However, more conservative glycemic targets are often recommended (e.g., fasting glucose <8 mmol/L) to reduce the risk of hypoglycemia, which can be particularly dangerous in older adults. Reduced kidney or liver function, common in older adults, may lower insulin requirements. Frequent monitoring is essential.
Missed Dose
If you miss a dose of Levemir, take it as soon as you remember, provided it is not too close to your next scheduled dose. Do not take a double dose to make up for the missed one. If you are unsure what to do, check your blood glucose level and consult your healthcare provider or diabetes nurse for guidance. Missing a dose may temporarily raise your blood sugar levels.
To help avoid missed doses, try to inject Levemir at the same time each day. Setting a daily reminder on your phone or linking the injection to a routine activity (such as brushing your teeth before bed) can be helpful.
Overdose
An insulin overdose can cause hypoglycemia, which can range from mild (treated by eating sugar or glucose) to severe (requiring assistance from another person or emergency medical treatment). Symptoms of severe hypoglycemia include confusion, seizures, and loss of consciousness.
- Mild hypoglycemia: Eat or drink 15–20 grams of fast-acting carbohydrates (glucose tablets, juice, regular soda). Recheck blood glucose in 15 minutes and repeat if needed
- Severe hypoglycemia: If the person is unconscious or unable to swallow, do not give food or drink by mouth. Administer glucagon injection if available, and call emergency services immediately. Place the person on their side (recovery position) to prevent choking
If you or someone you know experiences confusion, loss of consciousness, or seizures after taking insulin, call emergency services immediately. Severe untreated hypoglycemia can cause permanent brain damage or death.
How Do You Use the Levemir FlexTouch Pen?
Levemir FlexTouch is injected subcutaneously (under the skin) into the thigh, abdomen, or upper arm. Always use a new needle for each injection, perform a safety test before each dose, and rotate injection sites to prevent lipodystrophy.
Proper injection technique is essential for accurate dosing and safe insulin delivery. The FlexTouch pen is a pre-filled, dial-a-dose insulin pen that delivers doses from 1 to 80 units in increments of 1 unit. Below are detailed instructions for using the pen.
Step-by-step injection guide
- Prepare the pen: Wash your hands. Remove the pen cap. Check that the insulin solution is clear and colorless – do not use if it is cloudy, discolored, or contains particles
- Attach a new needle: Tear off the paper tab from a new needle. Screw or push the needle straight onto the pen. Remove the outer needle cap (keep it for later) and the inner needle cap (discard)
- Perform a safety test: Dial 2 units. Hold the pen with the needle pointing upward. Press the dose button fully. A drop of insulin should appear at the needle tip. Repeat if necessary until a drop appears. This removes air bubbles and confirms the pen is working
- Select your dose: Turn the dose selector to your prescribed dose. The dose can be corrected up or down without wasting insulin
- Choose and clean the injection site: Clean the skin with an alcohol swab. Recommended sites are the abdomen (at least 5 cm from the navel), the front of the thigh, or the upper arm. Rotate injection sites to prevent lipodystrophy
- Inject: Insert the needle into the skin. Press the dose button all the way in. Keep the needle in the skin for at least 6 seconds after the dose counter returns to 0 to ensure the full dose is delivered
- Remove and dispose: Pull the needle out of the skin. Place the outer needle cap back on the needle and unscrew it. Dispose of the used needle in a sharps container. Replace the pen cap
Always rotate your injection site within the same body region. For example, if you inject in the abdomen, move to a different spot within the abdomen each time, at least 1–2 cm from the last injection. Repeated injections in the same spot can cause lumps or indentations in the skin (lipodystrophy), which may affect how the insulin is absorbed.
What Are the Side Effects of Levemir?
The most common side effect of Levemir is hypoglycemia (low blood sugar), affecting more than 1 in 10 users. Other side effects include injection site reactions, lipodystrophy, and allergic reactions. Most side effects are manageable, but severe hypoglycemia and serious allergic reactions require immediate medical attention.
Like all medicines, Levemir can cause side effects, although not everybody gets them. The frequency of side effects is classified according to international conventions. Understanding these potential effects will help you recognize them early and seek appropriate care when needed.
Very Common
- Hypoglycemia (low blood sugar) – symptoms include sweating, trembling, hunger, dizziness, palpitations, confusion, blurred vision, weakness, and in severe cases, loss of consciousness or seizures
Common
- Injection site reactions – redness, swelling, itching, pain, or bruising at the injection site; usually mild and resolve within a few days
- Lipodystrophy – thickening (lipohypertrophy) or thinning (lipoatrophy) of fat tissue at frequently used injection sites; prevented by rotating injection sites
Uncommon
- Allergic reactions – skin rash, hives (urticaria), or itching spreading beyond the injection site
- Visual disturbances – temporary blurred vision, especially when insulin therapy is started or blood glucose control changes rapidly; usually resolves within weeks
- Peripheral edema – mild swelling of ankles or feet, particularly when insulin therapy is initiated; usually temporary
Rare
- Severe allergic reactions (anaphylaxis) – generalized skin rash, swelling of the face or throat, difficulty breathing, rapid heartbeat, drop in blood pressure; requires immediate emergency treatment
- Diabetic neuropathy – painful neuropathy may rarely occur with rapid improvement in blood glucose control (insulin neuritis); usually temporary
- Peripheral neuropathy – tingling, numbness, or pain in extremities; very rarely associated with insulin detemir itself
Seek emergency medical care if you experience signs of a severe allergic reaction (difficulty breathing, facial or throat swelling, rapid heartbeat) or severe hypoglycemia (loss of consciousness, seizures). Call emergency services immediately.
Long-term considerations
Long-term use of Levemir has been studied in clinical trials lasting several years. The safety profile is consistent with that of other basal insulins. Weight gain is a known effect of insulin therapy in general; however, clinical trials have consistently shown that Levemir is associated with less weight gain compared with NPH insulin, which is considered a clinical advantage. Antibodies to insulin detemir may develop but have not been shown to affect glycemic control or safety in clinical practice.
If you experience any side effects, even those not listed here, talk to your healthcare provider or pharmacist. You can also report side effects to your national pharmacovigilance authority (e.g., the FDA MedWatch program in the United States, the Yellow Card scheme in the United Kingdom, or the EMA in the European Union).
How Should You Store Levemir?
Store unopened Levemir FlexTouch pens in a refrigerator at 2–8°C. Once in use, the pen can be kept at room temperature (below 30°C) or in the refrigerator for up to 42 days. Do not freeze. Protect from direct light and heat.
Proper storage is critical to maintaining the effectiveness and safety of insulin. Insulin that has been improperly stored may lose potency, leading to poor blood glucose control. Follow these guidelines carefully.
Before first use (unopened)
- Store in the refrigerator at 2–8°C (36–46°F)
- Keep away from the freezer compartment – do not freeze
- Do not use Levemir if it has been frozen, even if it has thawed
- Keep the pen cap on to protect from light
- Check the expiry date on the label – do not use after the stated date
After first use (in-use)
- Store at room temperature below 30°C (86°F) or in the refrigerator at 2–8°C
- Use within 42 days (6 weeks) of first use, then discard even if insulin remains
- Always keep the pen cap on when not in use
- Do not store the pen with a needle attached – this can cause air bubbles, contamination, and leakage
- Do not expose to direct sunlight, excessive heat (e.g., in a car dashboard), or frost
When traveling, carry Levemir in an insulated bag to protect it from extreme temperatures. In hot climates, use a cooling wallet or insulated pouch. During air travel, always carry insulin in your hand luggage (cabin) – the cargo hold may reach freezing temperatures. Carry a letter from your healthcare provider confirming your need for insulin and injection supplies, especially when traveling internationally.
Signs of degraded insulin
Before each injection, visually inspect the insulin in the pen cartridge. Levemir should be a clear, colorless solution. Do not use it if:
- The solution appears cloudy, thickened, or discolored
- You can see particles or crystals in the liquid
- The pen has been dropped or damaged
- It has been stored outside recommended temperature conditions
What Does Levemir Contain?
Each milliliter of Levemir contains 100 units (14.2 mg) of insulin detemir as the active ingredient, along with several excipients including glycerol, phenol, metacresol, zinc acetate, and water for injections. The FlexTouch pen holds 3 mL (300 units) of solution.
Active ingredient
The active substance is insulin detemir, produced by recombinant DNA technology in Saccharomyces cerevisiae. Each mL contains 100 units of insulin detemir, equivalent to 14.2 mg. Each FlexTouch pre-filled pen contains 3 mL of solution, corresponding to 300 units of insulin detemir.
Excipients (inactive ingredients)
The inactive ingredients in Levemir serve specific purposes to maintain the stability, sterility, and proper pH of the insulin solution:
| Excipient | Function |
|---|---|
| Glycerol | Tonicity agent – makes the solution isotonic with body fluids |
| Phenol | Preservative – prevents microbial growth |
| Metacresol | Preservative – provides additional antimicrobial protection |
| Zinc acetate | Stabilizer – helps maintain insulin hexamer structure |
| Disodium phosphate dihydrate | Buffer – maintains pH of the solution |
| Sodium chloride | Tonicity agent – adjusts osmolality |
| Hydrochloric acid / Sodium hydroxide | pH adjustment – used as needed to achieve target pH |
| Water for injections | Solvent – provides the liquid base |
Physical description
Levemir FlexTouch is a disposable, pre-filled insulin pen with a green push-button and a pale green label. The pen is designed for use with NovoFine or NovoTwist disposable needles (sold separately). It delivers doses from 1 to 80 units in increments of 1 unit. The dose selector clicks audibly as units are dialed, and there is a dose window that shows the selected number of units.
Levemir FlexTouch pens are available in packs of 1, 5, or 10 pre-filled pens. Not all pack sizes may be available in every country.
Frequently Asked Questions About Levemir
Levemir FlexTouch (insulin detemir) is a long-acting basal insulin used to control blood sugar levels in adults and children aged 2 years and older with type 1 diabetes mellitus, and in adults with type 2 diabetes mellitus. It provides background insulin coverage for up to 24 hours and is used as part of a comprehensive diabetes management plan that includes diet, exercise, and blood glucose monitoring.
Levemir has a duration of action of up to 24 hours, depending on the dose. It typically starts working within 1 to 2 hours after injection and has a relatively flat action profile without a pronounced peak. Some patients may need to inject twice daily (morning and evening) for optimal 24-hour blood glucose coverage, while others achieve good control with a single daily injection.
The most common side effect is hypoglycemia (low blood sugar), which affects more than 1 in 10 users. Symptoms include sweating, trembling, hunger, dizziness, and confusion. Injection site reactions (redness, swelling, itching) are also common, affecting 1 to 10 in 100 users. Less common side effects include lipodystrophy, allergic reactions, and temporary visual disturbances. Severe side effects such as anaphylaxis are rare.
Yes, Levemir (insulin detemir) can be used during pregnancy when clinically needed. Clinical studies and observational data have not shown adverse effects on pregnancy or fetal health. Insulin requirements change significantly during pregnancy – typically decreasing in the first trimester and increasing during the second and third trimesters. Close blood glucose monitoring and regular dose adjustments by your healthcare provider are essential throughout pregnancy.
Levemir (insulin detemir) and Lantus (insulin glargine) are both long-acting basal insulins, but they differ in several ways. Levemir achieves its prolonged action through albumin binding and self-association, while Lantus forms microprecipitates at the injection site. Clinical studies show comparable blood glucose control (HbA1c reduction) with both. Levemir may be associated with slightly less weight gain. Some patients require twice-daily dosing with Levemir, while Lantus is typically given once daily. Levemir can be stored in use for 42 days compared to 28 days for Lantus. Your healthcare provider will select the best option based on your individual clinical profile.
Before first use, store Levemir in a refrigerator at 2–8°C (36–46°F). Do not freeze. Once in use, the pen can be kept at room temperature below 30°C (86°F) or in the refrigerator for up to 42 days (6 weeks). Always keep the pen cap on when not in use to protect from light. Never store the pen with a needle attached. Discard the pen after 42 days even if insulin remains.
References
This article is based on the following evidence-based sources and international guidelines:
- European Medicines Agency (EMA). Levemir – Summary of Product Characteristics (SmPC). Last updated 2024. Available at: www.ema.europa.eu
- U.S. Food and Drug Administration (FDA). Levemir (insulin detemir) – Prescribing Information. Novo Nordisk. Available at: www.accessdata.fda.gov
- American Diabetes Association (ADA). Standards of Care in Diabetes – 2024. Diabetes Care 2024;47(Suppl 1). doi:10.2337/dc24-SINT
- Davies MJ, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022;45(11):2753-2786.
- Heller S, et al. Insulin detemir, a long-acting insulin analog, is a safe and effective treatment for type 1 and type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism 2009;11(7):623-631.
- Mathiesen ER, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: A randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007;30(4):771-776.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd list (2023). Insulin preparations listed as essential medicines.
- National Institute for Health and Care Excellence (NICE). Type 1 diabetes in adults: diagnosis and management. NICE guideline NG17. Updated 2022.
- National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. NICE guideline NG28. Updated 2022.
- Plank J, et al. A direct comparison of insulin detemir and insulin glargine in patients with type 1 diabetes: results of a meta-analysis. Diabetic Medicine 2005;22(8):1107-1110.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians with specializations in endocrinology, clinical pharmacology, and internal medicine.
Medical Writing
iMedic Medical Editorial Team – specialists in endocrinology and clinical pharmacology with documented academic background and clinical experience in diabetes management.
Medical Review
iMedic Medical Review Board – independent panel of medical experts who verify all clinical content according to international guidelines (ADA, EASD, WHO, EMA, FDA).
Evidence standard: All medical claims in this article are based on Level 1A evidence (systematic reviews and meta-analyses of randomized controlled trials) or authoritative regulatory sources (EMA SmPC, FDA prescribing information). Content is reviewed according to the GRADE evidence framework.